Implications of a switch from prescription to over-the-counter status for allergy drugs

Current Allergy and Asthma Reports

Volumn 4, Issue 3, 2004, Pages 245-250

  Brass, Eric P ^a  

^a HARBOR UCLA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENERGIC RECEPTOR STIMULATING AGENT; AGENTS ACTING ON THE EYE; ANTIHISTAMINIC AGENT; BROMPHENIRAMINE; CETIRIZINE; CHLORPHENIRAMINE; CORTICOSTEROID; CROMOGLYCATE DISODIUM; DECONGESTIVE AGENT; DESLORATADINE; DIPHENHYDRAMINE; FEXOFENADINE; GENERIC DRUG; HYDROCORTISONE; LORATADINE; NON PRESCRIPTION DRUG; OXYMETAZOLINE; PHENIRAMINE; PHENYLEPHRINE; PSEUDOEPHEDRINE; TETRYZOLINE; ANTIALLERGIC AGENT;

ALLERGY; CLINICAL PRACTICE; COGNITIVE DEFECT; DRUG INDUSTRY; HEALTH CARE ACCESS; HEALTH CARE ORGANIZATION; HEALTH ECONOMICS; HEALTH PRACTITIONER; HUMAN; INSURANCE; MEDICAL DECISION MAKING; PATIENT CARE; PHYSICIAN; PRESCRIPTION; REVIEW; SEDATION; SELF EVALUATION; HEALTH CARE DELIVERY; PERENNIAL RHINITIS; SELF CARE;

ANTI-ALLERGIC AGENTS; DELIVERY OF HEALTH CARE; DRUGS, NON-PRESCRIPTION; HUMANS; PRESCRIPTIONS, DRUG; RHINITIS, ALLERGIC, PERENNIAL; SELF CARE;

EID: 3042587323     PISSN: 15297322     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11882-004-0033-1     Document Type: Review

References (29)

1. Crystal-Peters J, Crown W, Goetzel R, Schutt D: The cost of productivity losses associated with allergic rhinitis. Am J Manag Care 2000, 6:373-378.
2. Storms W, Meltzer E, Nathan R, Selner J: The economic impact of allergic rhinitis. J Allergy Clin Immunol 1997, 99:S820-S824.
3. Nathan R, Meltzer E, Slener J, Storms W: Prevalence of allergic rhinitis in the United States. J Allergy Clin Immunol 1997, 99:S808-S814.
4. Storms W, Meltzer E, Nathan R, Selner J: Allergic rhinitis: the patient's perspective. J Allergy Clin Immunol 1997, 99:S825-S828.
5. Zuckerman G, Bielory L: Complementary and alternative medicine herbal therapies for atopic disorders. Am J Med 2002, 113(Suppl 9A):47S-51S.
6. Rosenau P: Rx-to-OTC switch movement. Med Care Rev 1994, 51:429-466.
7. Brass EP: Changing the status of drugs from prescription to over-the-counter availability. N Engl J Med 2001, 345:810-816.
8. Food and Drug Administration: Cold, cough, allergy, bronchodilator, and antihistamine drug products for over-the-counter use; final monograph for combination drug products. Final rule. Fed Register 2002, 67:78158-78172.
9. Brass EP, Weintraub M: Label development and the label comprehesion study for over-the-counter drugs. Clin Pharmacol Ther 2003, 74:406-412.
10. Food and Drug Administration: Joint meeting nonprescription drug advisory committee and pulmonary-allergy advisory committee. http://www.fda.gov/ohrms/dockets/ac/ 01/transcripts/3737t1-01.pdf. Accessed November 24, 2003.
11. Meltzer E, Group NS: Efficacy and patient satisfaction with cromolyn sodium nasal solution in the treatment of seasonal alergic rhinitis: a placebo-controlled study. Clin Ther 2002, 24:942-952.
12. Lipsky MS, Waters T: The "prescription-to-OTC switch" movement: its effects on antifungal vaginitis preparations. Arch Fam Med 1999, 8:297-300.
13. Chih-Wen S, Asch S, Fielder E, et al.: Usage patterns of over-the-counter phenazopyridine (Pyridium). J Gen Intern Med 2003, 18:281-287.
14. Sampey C, Follin S: Second-generation antihistamines: the OTC debate. J Am Pharm Assoc (Wash) 2001, 41:454-457.
15. Kay G, Berman B, Mockoviak S, et al.: Initial and steady-state effects of diphenhydramine and loratadine on sedation, cognition, mood, and psychomotor performance. Arch Intern Med 1997, 157:2350-2356.
16. Kaliner M: H1-antihistamines in the elderly. Clin Allergy Immunol 2002, 17:465-481.
17. Weiler J, Bloomfield J, Woodworth G, et al.: Effects of fexofenadine, diphenhydramine, and alcohol on driving performance: a randomized, placebo-controlled trial in the Iowa driving simulator. Ann Intern Med 2000, 132:354-363.
18. Hennessy S, Strom B: Nonsedating antihistamines should be preferred over sedating antihistamines in patients who drive. Ann Intern Med 2000, 132:405-407.
19. Bender B, Berning S, Dudden R, et al.: Sedation and performance impairment of diphenhydramine and second-generation antihistamines: a meta-analysis. J Allergy Clin Immunol 2003, 111:770-776.
20. Meltzer E, Ehrlich P: A step approach to the clinical management of allergic rhinitis: prescription and over-the-counter therapeutic reference summary. Manag Care Interface 1999, 12:70-77.
21. Conner S: Evaluation and treatment of the patient with allergic rhinitis. J Fam Pract 2002, 51:883-890.
22. Meltzer E, Nathan R, Selner J, Storms W: Quality of life and rhinitic symptoms: results of a nationwide survey with the SF-36 and RQLQ questionnaires. J Allergy Clin Immunol 1997, 99:S815-S819.
23. Togias A: Rhinitis and asthma: evidence for respiratory system integration. J Allergy Clin Immunol 2003, 111:1171-1183.
24. American Academy of Allergy Asthma and Immunology, American College of Allergy Asthma and Immunology, Joint Council of Allergy Asthma and Immunology: Insurance coverage for H1-antihistamines: implications for quality healthcare and public safety. http://allergy.mcg.edu/otcAH/antihis.pdf. Accessed November 24, 2003.
25. Gossel T: Implications of the reclassification of drugs from prescription-only to over-the-counter status. Clin Ther 1991, 13:200-215.
26. Ryan M, Yule B: Switching drugs from prescription-only to over-the-counter availability: economic benefits in the United Kingdom. Health Policy 1990, 16:233-239.
27. Schering-Plough: Schering-Plough reports financial results for 2003 third quarter. http://www.sch-plough.com/news/2003/financial/3q03_earnings.pdf. Accessed November 17, 2003.
28. Pfizer: 2003 third quarter earnings report. http://www.pfizer.com/download/news/2003Q3_earnfin4.pdf. Accessed November 17, 2003.
29. Aventis: 2003 third quarter earnings report. http://www.aventis.com/main/attachments/48323520031029223717.xls. Accessed November 17, 2003.